This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antimicrobial Resistance
November 2, 2022 | 1-Day Digital Conference
Digital Conference8:00AM EST // 12:00PM GMT // 1:00PM CET
Menu
Key Sessions
Marc Gitzinger
Innovation Motivation: Drug Discovery and Development
BEAM Alliance, Switzerland
Mateusz Hasso-Agopsowicz
Innovation Motivation: Strategies for optimizing the use of vaccines against AMR and the vaccine pipeline
WHO, Switzerland
keyboard_arrow_right

Antimicrobial Resistance - EST/EDT (Eastern Daylight, GMT-4)

keyboard_arrow_leftSearch & Filter
search
Antimicrobial Resistance - EST/EDT (Eastern Daylight, GMT-4)
search
Showing 1 of 1 Streams
08:00 - 08:15
Welcoming Remarks
08:15 - 08:45
Supporting evidence-based decision making across the AMR research and development value chain
  • What is the current state of public funding for AMR R&D globally?
  • Is this funding being translated into products that mitigate AMR?
  • What are governments doing to incentivize development and access to priority antimicrobials?
  • Lesley Ogilvie - Interim Secretariat Lead, Global AMR R&D Hub, Germany
08:45 - 09:15
The UK Antibiotic Subscription Pilot: Does the model provide the needed pull incentive?
09:15 - 09:45
Data for Action: Driving change in how we address AMR
  • How can AMR surveillance, epidemiology, and economic impact data inform clinical care and practice?
  • How does industry leverage AMR data to strengthen health systems and decrease the burden of AMR?
  • How can the research community better leverage data to impact positive change?

  • Bruce Altevogt - VP and Head External Medical Engagement, Hospital Business Unit, Pfizer, USA
09:45 - 10:15
Working with politicians and policymakers to contain and control AMR
10:15 - 10:35
Coffee Break & Networking
10:35 - 11:05
Innovation Motivation: Artificial Intelligence to Tackle AMR
11:05 - 11:35
Innovation Motivation: Artificial Intelligence Approaches for Antibiotic Discovery
11:35 - 11:55
Coffee Break & Networking
11:55 - 12:25
Innovation Motivation: Innovation Experiences from Africa-led Drug Discovery at H3D
  • Highlighting efforts taken to tackle Tuberculosis AMR
  • Efforts towards addressing drug-resistant ESKAPE pathogens
  • Malaria: A success story



  • Vinayak Singh - Senior Research Officer, Drug Discovery and Development Centre (H3D), South Africa
12:25 - 12:55
Innovation Motivation: Drug Discovery and Development
  • Marc Gitzinger - President, BEAM Alliance, Switzerland
12:55 - 13:25
Innovation Motivation: Vaccines to help address the threat of AMR
13:25 - 13:55
Innovation Motivation: Strategies for optimizing the use of vaccines against AMR and the vaccine pipeline
13:55 - 14:55
End of Day/ Networking on the Platform
Filter
Topics
Choose Day